ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?

•ALK/ROS1-rearranged NSCLC NSCLC patients seem to be at increased risk of VTEs•However, this evidence comes from retrospective, heterogeneous studies, and the impact of anticancer treatments on this risk in poorly investigated•We performed a meta-analysis of prospective data to assess the risk of VTEs in ALK/ROS1-rearranged NSCLC patients•We showed that TKIs targeting ALK/ROS1-rearranged NSCLC did not significantly increase VTEs risk compared to platinum-based CT•Our data support the idea that VTE risk in ALK/ROS1-rearranged NSCLC patients is related to the molecular driver irrespectively of the treatment